332 related articles for article (PubMed ID: 33769675)
21. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies.
Liu J; Tarasenko L; Terra SG; Huyck S; Wu L; Pong A; Calle RA; Gallo S; Darekar A; Mancuso JP
Diab Vasc Dis Res; 2019 Sep; 16(5):415-423. PubMed ID: 31081371
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
Ji L; Jiang X; Hao Q; Cheng Z; Wang K; Pang S; Liu M; Guo Y; Chen X; Su X; Ning T; Liu J; Bian F; Li Y; Zhang Z; Song W; Sun J
Diabetes Obes Metab; 2023 May; 25(5):1229-1240. PubMed ID: 36594724
[TBL] [Abstract][Full Text] [Related]
24. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Wojeck BS; Inzucchi SE; Neeland IJ; Mancuso JP; Frederich R; Masiukiewicz U; Cater NB; McGuire DK; Cannon CP; Yaggi HK
Sleep Breath; 2023 May; 27(2):669-672. PubMed ID: 35596030
[TBL] [Abstract][Full Text] [Related]
25. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
Lancet Healthy Longev; 2023 Apr; 4(4):e143-e154. PubMed ID: 37003273
[TBL] [Abstract][Full Text] [Related]
26. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
Heymsfield SB; Raji A; Gallo S; Liu J; Pong A; Hannachi H; Terra SG
Obesity (Silver Spring); 2020 Apr; 28(4):724-732. PubMed ID: 32202075
[TBL] [Abstract][Full Text] [Related]
28. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
Liu J; Pong A; Gallo S; Darekar A; Terra SG
Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV.
Strojek K; Pandey AS; Dell V; Sisson M; Wang S; Huyck S; Liu J; Gantz I
Diabetes Ther; 2021 Apr; 12(4):1175-1192. PubMed ID: 33694093
[TBL] [Abstract][Full Text] [Related]
30. [Ertugliflozin alone and in fixed-dose combinations : «pass of three»].
Scheen AJ
Rev Med Liege; 2020 Sep; 75(9):626-632. PubMed ID: 32909416
[TBL] [Abstract][Full Text] [Related]
31. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Masiukiewicz U; Charbonnel B; Frederich R; Gallo S; Cosentino F; Shih WJ; Gantz I; Terra SG; Cherney DZI; McGuire DK;
N Engl J Med; 2020 Oct; 383(15):1425-1435. PubMed ID: 32966714
[TBL] [Abstract][Full Text] [Related]
33. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J; Zeng L; Zhang Y; Qu S; Wang X; Li P; Fu L; Ma B; Ye S; Sun J; Lu W; Liu Z; Chen D; Cheng Z; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 Aug; 23(8):1754-1764. PubMed ID: 33769656
[TBL] [Abstract][Full Text] [Related]
34. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
35. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110
[TBL] [Abstract][Full Text] [Related]
36. The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies.
Gallo S; Raji A; Calle RA; Pong A; Meyer C
Diabetes Obes Metab; 2020 Dec; 22(12):2267-2275. PubMed ID: 32700393
[TBL] [Abstract][Full Text] [Related]
37. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
Cowart K; Carris NW
Expert Opin Pharmacother; 2021 Feb; 22(2):163-165. PubMed ID: 32962443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
